Metsera (NASDAQ:MTSR) Releases Earnings Results

Metsera (NASDAQ:MTSRGet Free Report) posted its earnings results on Wednesday. The company reported ($3.52) EPS for the quarter, Zacks reports.

Metsera Price Performance

Metsera stock traded down $0.70 during trading on Wednesday, reaching $28.46. The company had a trading volume of 31,153 shares, compared to its average volume of 664,188. Metsera has a 1-year low of $23.08 and a 1-year high of $32.81.

Analysts Set New Price Targets

Several research firms have commented on MTSR. Guggenheim began coverage on Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price objective on the stock. Evercore ISI initiated coverage on shares of Metsera in a report on Tuesday, February 25th. They set an “outperform” rating on the stock. Bank of America assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on shares of Metsera in a research note on Tuesday, February 25th. They set an “overweight” rating on the stock.

Get Our Latest Research Report on MTSR

About Metsera

(Get Free Report)

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

See Also

Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.